Faculty Information - 佐藤　加代子

Social activities

Research grants & projects

Academic society memberships

Education

（Last updated : 2022-08-03 14:36:09）

佐藤　加代子
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine

Position

■ Books

Chapter contribution　

Chapter 4. Myocardial Infarction, Evidence - Based Cardiology 2002

■ Published papers

1.	Case report	A case of heterozygous familial hypercholesterolemia requiring strict low-density lipoprotein cholesterol management with proprotein convertase subtilisin/kexin 9 inhibitor after coronary artery bypass grafting 2021/03/18
2.	Original article	New Strategy to Prevent Acute Myocardial Infarction by Public Education: A Position Statement of the Committee on Public Education About Emergency Medical Care of the Japanese Circulation Society 2021/02
3.	Original article	Oxidative stress-responsive apoptosis-inducing protein in patients with heterozygous familial hypercholesterolemia. 2021
4.	Original article	Myocardial Flow Reserve in Coronary Artery Disease with Low Attenuation Plaque: Coronary CTA and 13N-ammonia PET Assessments. 2020/12
5.	Original article	Guidelines on the Clinical Evaluation of Medicinal Products for Treatment of Dyslipidemia. 2020/11
6.	Original article	An accumulation of two populations of dendritic cells in skin-draining lymph nodes in response to the expression of thymic stromal lymphopoietin in the skin. 2020
7.	Review article	Gender Medicine Gender Differences in Cardiovascular Disease 2019/08
8.	Original article	Statement for Appropriate Clinical Use of PCSK9 Inhibitors. 2018/08
9.	Original article	P-Selectin Glycoprotein Ligand-1 (PSGL-1) Expressing CD4 T Cells Contribute Plaque Instability in Acute Coronary Syndrome. 2018/07
10.	Original article	PSGL-1 expressing CD4 T cells contribute plaque instability in acute coronary syndrome. 2018/05
11.	Original article	Oxidative Stress-Responsive Apoptosis Inducing Protein (ORAIP) Plays a Critical Role in the Cardiac Injury in Patients with Heart Failure. 2017/12
12.	Original article	Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Disease 2017 2017/06
13.	Original article	The Role of IL17 and IL17+Th17 in the Atherosclerotic Development and renal dysfunction 2017
14.	Original article	The Role of IL17 and IL17+Th17 in the Atherosclerotic Development. 2016
15.	Original article	Sudden cardiac arrest secondary to cardiac amyloidosis in a young woman with cryopyrin-associated periodic syndrome. 2015/04
16.	Original article	Helper T Cell Diversity and Plasticity -Possible Role in Cardiovascular Disease-. 2014/12
17.	Original article	THE ROLE OF PSGL-1-EXPRESSING CD4 T CELLS IN THE DEVELOPMENT OF ATHEROSCLEROSIS. 2014
18.	Original article	Insufficient ascorbic acid intake during gestation induces abnormal cardiac dilation in fetal and neonatal SMP30/GNL knockout mice 2013/05
19.	Original article	THE ROLE OF PSGL-1-EXPRESSING CD4 T CELLS IN THE CULPLET LESION OF ACUTE CORONARY SYNDROME 2013
20.	Original article	PSGL-1-expressing CD4 T cells induce endothelial cell apoptosis in perimenopausal women 2012/03
21.	Original article	High fat diet in apolipopretein E-deficient mice decreased nephrin phosphorylation and induced proteinuria 2011
22.	Other	PSGL-1-Expressing CD4 T Cells Induce Endothelial Cell Apoptosis in Perimenopausal Women 2010/09
23.	Other	CD4 T Cell Dysfunction in Perimenopausal Women: The Mechanism of Acceleration of Atherosclerosis 2010
24.	Other	Pitavastatin Prevents Atherosclerotic Plaque Development via Inhibition of TRAIL Expression on CD4 T Cells 2010
25.	Other	PSGL-1expressing CD4 T cell in atherosclerotic plaque 2010
26.	Other	Role of PSGL-1 Expressing CD4 T Cells in Acute Coronary Syndrome 2010
27.	Other	Role of PSGL-1 Expressing CD4 T Cells in Plaque Instability 2010
28.	Other	Statins Protect In-stent Restenosis in Patients with High Adiponectin by Improving the LDL to HDL Cholesterol Ratio 2010
29.	Original article	Statins reduce endothelial cell apoptosis via inhibition of TRAIL expression on activated CD4 T cells in acute coronary syndrome. 2010
30.	Original article	Functional profile of activated dendritic cells in unstable atherosclerotic plaque. 2007/03
31.	Original article	Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-alpha. 2006/12
32.	Original article	T cell recognition and killing of vascular smooth muscle cells in acute coronary syndrome. 2006/05
33.	Original article	TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque 2006/01
34.	Original article	T cells in the atherosclerosis plaque: A role for TRAIL-producing T cells in the rupture of the atherosclerotic plaque 2006
Display 5 items
Display all(34)

■ Academic conference presentation

1.	Front Lines of Optimal Management of Atherosclerosis Risks　Lipoprotein(a) is Residual Risk Factor for the Atherosclerotic Cardiovascular Disease in the Well-controlled LDL-C Era 2021/03/27
2.	Aortic Valve Calcification and Prognostic Evaluation in Patients with Heterozygous Familial Hypercholesterolemia 2021/03
3.	Lipoprotein(a) is residual risk factor for the atherosclerotic cardiovascular disease in patients with LDL-C hypercholesterolemia 2021/03
4.	PCSK9 Gene Mutations Have a Higher Risk of Cardiovascular Events than LDL Receptor Abnoramalities in Heterozygous Familial Hypercholesterolemia 2021/03
5.	家族性高コレステロール血症における動脈硬化進展と炎症Inflammation and atherosclerotic development in the patients with familial hypercholesterolemia 2021/03
6.	Aortic Valve Calcification Predicts Subclinical Coronary Atherosclerosis in Heterozygous Familial Hypercholesterolemia Patients with High LP (a) Levels 2020/07
7.	High Apolipoprotein-B Level is a Risk Factor of Secondary Cardiovascular Incidence in Patients with Familial Hypercholesterolemia 2020/07
8.	Activation of Effector Memory and Effector T Cells in Patients with Familial Hypercholesterolemia. 2019/12/11
9.	Aortic Valve Calcification and Subclinical Coronary Atherosclerosis in Japanese Heterozygous Familial Hypercholesterolemia Patients With High Lp(a) Levels 2019/11/17
10.	Genetic Diagnosis of Familial Hypercholesterolemia and the Risk of Cardiovascular Events 2019/07/11
11.	Progeroid syndrome with focal segmental glomeruloscrelosis due to ZMPSTE24 mutations 2019/06/16
12.	Genetic Diagnosis of Familial Hypercholesterolemia and the Risk of Cardiovascular Events 2019/03/29
13.	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK-9) Inhibitor Improve Lipid Profile and Vascular Atherosclerotic Plaque Formation in Japanese High-Risk Familia Hypercholesterolemia 2018/11/12
14.	Aortic Vale calcification and coronary atherosclerosis in familial hypercholesterolemia patients 2018/09/22
15.	The role of ORAIP for the coronary artery plaque instability in Familial Hypercholesterolemia 2018/09/22
16.	Underdiagnosis and non-treatment of heterozygous familial hypercholesterolemia in association with cardiovascular disease 2018/08/28
17.	Insight into Polygenetic Abnormalities in Japanese Heterozygous Familial Hypercholesterolemia 2018/06/10
18.	Proprotein Convertase Subtilisin/kexin Type 9 (PCSK-9) inhibitors Improve Lipid Profile and Vascular Atherosclerotic Plaque in Familial Hypercholesterolemia 2018/06/09
19.	Aortic Valve Calcification and Subclinical Coronary Atherosclerosis Using Computed Tomography in Japanese Heterozygous Familial Hypercholesterolemia Patients with Gene Mutation 2018/03/25
20.	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK-9) Inhibitors Improve Lipid Profile and Vascular Atherosclerotic Plaque Formation in High-risk Familial Hypercholesterolemia. 2018/03/25
21.	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK-9) Inhibitors Improve Lipid Profile and Vascular Atherosclerotic Plaque Formation in High-risk Familial Hypercholesterolemia. 2018/03/25
22.	Heterozygous Familial Hypercholesterolemia: Insight into Polygenetic Abnormalities in Japanese Patients 2018/03/24
23.	Assessment of Cardiovascular Atherosclerosis of Heterozygous Familial Hypercholesterolemia (hFH) Using 320-detector Row Coronary CT 2018/03/23
24.	The Strict Management of Low-Density Lipoprotein Cholesterol in Heterozygous Familial Hypercholesterolemia for the Secondary Prevention of Cardiovascular Disease 2018/03/23
25.	Underdiagnosis and Non-treatment of Heterozygous Familial Hypercholesterolemia in Association with Cardiovascular Disease 2018/03/23
26.	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK-9)Inhibitors Improve Lipid Profile and Vascular Atherosclerotic Plaque Formation in High-Risk Familial Hypercholesterolemia 2018/03/11
27.	Polygenetic Abnormalities in Japanese Patients With Heterozygous Familial Hypercholesterolemia 2018/03/10
28.	Insight into Polygenetic Abnormalities in Japanese Heterozygous Familial Hypercholesterolemia 2018/01/06
29.	Dipeptidy1 peptidase4(DPP-4) signaling in T cells contributes atherosclerotic development and dysfunction 2017/12/12
30.	Underdiagnosis and Undertreatment of Heterozygous Familial Hypercholesterolemia in Association With Cardiovascular Disease 2017/11/14
31.	Aortic valve calcification and coronary plaque morphology in Japanese heterozygous familial hypercholestestreolemia patients with gene mutation 2017/11/11
32.	Gender Difference of Atherosclerotic Development in Heterozygous Familial Hypercholesterelemia 2017/09/16
33.	Under-diagnosis and Under-treatment of Heterozygous Familial Hypercholesterelaemia in Patients with Cardiovascular Diseases 2017/08/29
34.	Polygenetic Abnormalities in Japanese Patients with Heterozygous Familial Hypercholesterolemia 2017/07/07
35.	Assessment of cardiovascular atherosclerosis of heterozygous familial hypercholesterolemia (hFH) using 320-slice coronary CT 2017/07/06
36.	Marked Elevation of Plasma Levels of Oxidative stress-Responsive Apoptosis Inducing Protein (ORAIP) in Patients with Heterozygous Familial Hypercholesterolemia (heFH) 2017/03/19
37.	Underdiagnosis and Under Treatment of Heterozygous Familial Hypercholesterelemia in Cardiovascular Diseases 2017/03/19
38.	The prevalence of polygenetic abnormality in heterozygous familial hypercholesterolemia 2017/03/18
39.	Activation of Effector Memory and Effecter T Cells in Patients with Heart Failure 2017/03/17
40.	Rapid Resolution of Tendon Xanthomas in Elder Heterozygous Familial Hyperchorestelemia Treated With Evolocumab 2017/03/17
41.	Activation of Effector Memory T Cells in Patients with Heart Failure 2016/12/17
42.	The roll of potassium channel on T cell for effector memory and effecter T cells in patients with heart failure 2016/12/07
43.	Impact of PHQ-2 screening in outpatients with heart failure: A Multicenter prospective observational study 2016/08/30
44.	THE ROLE OF PSGL-1-EXPRESSING CD4 T CELLS IN THE ATHEROSCLEROTIC DEVELOPMENT AND PLAQUE INSTABILITY 2016/08/25
45.	Heterozygous Familial Hypercholesterelemia with Cardiovascular Diseases 2016/07/15
46.	Dipeptidyl Peptidase 4 (DPP-4) Inhibitor Improve the Atherosclerosis and Glomerular Tissue Damage through Suppressing the Eff ector T Cell Function 2016/07/14
47.	Activation of Central Effector Memory and Effecter T Cells in Patients with Heart Failure 2016/03/19
48.	Dipeptidyl Peptidase 4 (DPP-4) Inhibitor Improve the Atherosclerosis and Glomerular Tissue Damage through Suppressing the Effector T Cell Function 2015/12/11
49.	Underdiagnosis and Undertreatment of Heterozygous Familial Hypercholesterelemia in Cardiovascular Diseases 2015/12/11
50.	The role of PSGL-1 on T cells in the atherosclerotic development and plaque instability 2015/11/19
51.	DPP-4 signaling in T cells contributes atherosclerotic development and renal dysfunction. 2015/05/25
52.	Dipeptidyl Peptidase 4(DPP-4) Signaling in T Cells Contributes Atherosclerotic Development and Glomerular Tissue Damage 2015/04/25
53.	Soluble TRAIL is a Predictive Marker of Future Cardiac Event in Acute Coronary Syndrome 2015/04/25
54.	Amiodarone Treatments Improve the Effector Function of Memory T Cells in Heart Failure 2014/12/12
55.	Amiodarone Treatments Improve the Inflammation in Heart Failure. 2014/11/18
56.	IL17 Contribute to the Atherosclerotic Development and the Initiation of Chronic Kidney Disease. 2014/11/18
57.	Ventricular fibrillation in a young woman with cryopyrin-associated periodic syndrome. 2014/08/30
58.	Atorvastatin improved the atherosclerotic renal dysfunction by the inhibitation of inflammation in kidney. 2014/07/11
59.	The role of T cell in the atherosclerotic plaque development 2014/05/29
60.	IL17 contribute to the atherosclerotic development and the initiation of chronic kidney disease (CKD) in ApoE deficient mouse 2014/04/15
61.	Statin improved the atherosclerotic renal dysfunction 2014/04/15
62.	Amiodarone Treatments Improve the Inflammation in Heart Failure Patient 2014/03/23
63.	The Role of PSGL-1 on Leucocytes in Acute Coronary Syndrome and the Development of Atherosclerosis 2014/03/23
64.	Amiodarone Treatments Improve the Inflammation in Heart Failure Patients with Nonischemic Cardiomyopathy 2013/12/11
65.	ROLE OF PSGL-1 EXPRESSING CD4 T CELLS IN ACUTE CORONARY SYNDROME 2013/06/04
66.	PSGL-1+ CD4+ T Cells Contribute Atherosclerotic Plaque Instability 2012/12/07
67.	PSGL-1 Expressing CD4+ T-cells in Acute Coronary Syndrome 2012/03/27
68.	INFγ and IL-17-Producing T-Cells Contribute to the Microalbuminuria with the Dysfunction of Podocytes 2012/03/16
69.	Th1 and Th17 T cells contribute to the microalbuminuria with the dysfunction of podocytes 2011/12/09
70.	PSGL-1 Expressing CD4 T cells Contribute Plaque Instability in ACS 2011/11
71.	PSGL-1 expressing CD4 T cells in plaque instability 2011/08
72.	Role of T cells in Essential Hypertension 2011/08
73.	Th1 T cells and Th17 cells contribute to the microalbuminuria in apolipoprotein E-deficient mice 2011/08
74.	Roles of CD4 T cells in the vulnerable plaque formation. 2010/12
75.	PSGL-1-expressing CD4 T cells induce endothelial apoptosis in perimenopausal women. 2010/08
76.	The role of PSGL-1-expressing CD4 T cells in perimenopausal women 2010/07
77.	PSGL-1 is a key molecule for plaque stablility in acute coronary syndrome 2009/06
78.	(FRS)Soulble TRAIL is a predictive marker of vulnerable patients with acute coronary syndromes 2009/03
79.	Novel Biomarkers and Patholphysiology of ACS PSGL-1 Expressed CD4T Cells in the Culprit Lesion of Acute Coronary Syndrome 2009/03
80.	Novel Biomarkers and Patholphysiology of ACS Soluble TRAIL is a Predictive Marker of Vulnerable Patients with Acute Coronary Syndromes) 2009/03
81.	PSGL-1 expressed CD4 T cells in culprit coronary artery of acute coronary syndrome 2009/03
82.	PSGL-1 Expressed CD4 T Cells in the Culprit Lesion of Acute Coronary Syndrome 2009/03
83.	PSGL-1 is a Key Molecule for Endothelial Injury in Perimenopausal Women) 2009/03
84.	PSGL-1-Expressing CD4 T Cells are Enriched in Culprit Coronary Artery Lesion of Acute Coronary Syndrome 2008/11
85.	PSGL-1-expressing CD4 T Cells Induce Endothelial Injury in Perimenopausal Women with Low Estrogen Levels 2008/11
86.	Soluble TRAIL in Peripheral Blood is a Novel Marker for Acute Coronary Syndromes 2008/11
87.	D4 T Cells Induce Endothelial Apoptosis via PSGL-1 in Perimenopausal Women with Low Estrogen Levels 2008/06
88.	Soluble TRAIL is a Novel Marker for Acute Coronary Syndromes 2008/06
89.	CD4 T Cell Dysfunction Induces Endothelial Apoptosis in Perimenopausal Women with Low Estrogen Levels 2007/11
90.	HMG-CoA Reductase Inhibitors reduce Apoptosis of Endothelial Cells induced by TRAIL-expressing CD4 T cell in Acute Coronary Syndromes 2007/11
91.	Lack of Dehydroepiandrosterone-sulfate (DHEAS) contributes to CD4 T Cell-Induced Endothelial Apoptosis in Perimenopausal Women 2007/11
92.	TNFα Renders Vascular Smooth Muscle Cells in the Atherosclerotic Plaque Susceptible to Apoptosis by Inducing the Expression of DR5 2007/09
93.	急性冠症候群においてスタチンはTRAIL発現CD4陽性T細胞により誘導される内皮細胞アポトーシスを抑制する(Statins Reduced TRAIL-Expressing CD4 T Cell Induced Endothelial Cells Apoptosis in Acute Coronary Syndrome) 2007/03
94.	Metabolic syndrome contributes to aspirin-resistant thromboxane biosynthesis via inducing platelets COX-2 expression in patients with stable angina 2006/11
95.	T Cell Receptor Signaling and Synapse Formation in T Cells From Patients With Acute Coronary Syndrome. Sergey Pryshchep 2006/11
96.	TNFα renders vascular smooth muscle cells in the atherosclerotic plaque susceptible to apoptosis by inducing the expression of Death Receptor 5 2006/11
97.	CD4 T Cell Dysfunction of Perimenopausal Women: The Role of Estrogen in Atherosclerosis 2006/09
98.	CD4 T Cell Dysfunction of Perimenompausal Women; The Role of Estrogen in Atherosclerosis 2006/06
99.	安定狭心症患者においてメタボリック症候群は血小板COX-2発現誘導を介してアスピリン抵抗性トロンボキサン生合成に関与する(Metabolic Syndrome Contributs to Aspirin-resistant Thromboxane Biosynthesis via Inducing Platelets COX-2 Expression in Patients with Stable Angina) 2006/03
100.	Immunoregulatory Function of Interferon-a-Producing Plasmacytoid Cells in the Athrtosclerotic Plaque 2005/11
101.	T cells in the atherosclerotic plaque - A role for TRAIL-producing T cells in the rupture of the atherosclerotic plaque 2005/09
102.	T cells in the atherosclerotic plaque-A role for TRAIL-producing T cells in the rupture of the atherosclerotic plaque 2005/08
103.	CD4 T Cells from Patients with Acute Coronary Syndromes Form Stable Immunological Synapse with Vascular Smooth Muscle Cells and Induce Cell Death 2004/11
104.	T Cells Infiltrating Carotid Plaque Induce Vascular Smooth Muscle Cell Apoptosis through the Deat Receptor Ligand Apo2L/TRAIL 2004/11
105.	T cells kill vascular smooth muscle cells via the death pathway –A role for TRAIL-producing T cells in the rupture of the atherosclerotic plaque 2004/07
106.	T-cell-mediated injury of vascular smooth muscle cells in acute coronary syndromes: A role for the death receptor ligand Apo2L/TRAIL 2003/11
107.	ステントをいれている時期における急性心筋梗塞(MI)に対するPCIを受ける予定の非常に高齢な患者(>85歳)の入院中の転帰(In-hospital outcome of very elderly patients (>85 years) undergoing PCI for acute myocardial infarction (MI) in stent era) 2001/03
108.	Expression of peroxisome proliferator-activated receptor in human vascular endothelial cells 1998/10
109.	Effect of estrogen on synthesis of prostacyclin in cultured in bovine endothelial cell 1997/06
110.	Coagulopathy in patients with dissecting aortic aneurysm: Distinguishing thrombosed type from open communicated type 1995/08
Display 5 items
Display all(110)

■ Social activities

1.	2021/02	（座長）一般演題 Infection/Inflammation/Immunity 1 ／第85回日本循環器学会学術集会
2.	2019/12	(Chairperson) Poster 3 Cardiac hypertrophy and heart failure／36th International Society For Heart Research Japanese Section Annual Meeting 2019 (CVMW 2019)
3.	2019/07	(Chairperson) Poster 1-23 : Atherothrombotic dieseases/The 51st Annual Scientific Meeting of the Japan Atherosclerosis Society
4.	2018/03	(Chairpersons) Oral Presentation (English) 47 Atherosclerosis (Basic/Clinical/Treatment)/The 82nd Annual Scientific Meeting of the Japanese Circulation Society
5.	2018/03	(Moderator) Atherosclerosis/The 82nd Annual Scientific Meeting of the Japanese Circulation Society
6.	2016/07	(Moderator)Plenary Lecture Imaging and Targeting Inflammation in Acute Myocardial Infarction/the 10th Congress of the Asian-Pacific Society of Atherosclerosis and Vascular Diseases (APSAVD)
7.	2016/03	(Moderator)Cardiomyopathy 1/The 80th Annual Scientific Meeting of the Japanese Circulation Society
8.	2016/03	(Moderator)Preventive Medicine/Epidemiology/Education 2/The 80th Annual Scientific Meeting of the Japanese Circulation Society
9.	2015/04	(Moderator)InfectionInflammationImmunity/The 79th Annual Scientific Meeting of the Japanese Circulation Society
Display 5 items
Display all(9)

■ Research grants & projects

1997～1998

Grant-in-Aid for Scientific Research from the Ministry of Education, Science, and Culture of Japan, "Effect of estrogen on synthesis of prostacyclin in cultured bovine endothelial cells (Key Word : )

■ Academic society memberships

1.		American Colladge of Cardiology (ACC)
2.		Eouropian Society of Cardiology (ESC)
3.		International Atherosclerosis Society (IAS)

■ Education

1.		Faculty of Medicine, Tokyo Women's Medical University, Graduated,
2.	1997/10 Degree Acquisition	Tokyo Women's Medical University,